Drug Profile
NP 202 - Armaron Biosciences
Alternative Names: NP 202 - NeuProtectLatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator NeuProtect
- Developer Armaron Biosciences
- Class Anti-ischaemics; Antiarrhythmics; Flavonoids; Small molecules
- Mechanism of Action Death-associated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myocardial infarction; Paroxysmal atrial fibrillation
Most Recent Events
- 09 Aug 2021 NP 202 is still in phase II trial in Myocardial infraction in USA, New Zealand, Australia (PO) (ACTRN12615000609550) (NCT02557217)
- 09 Aug 2021 NP 202 is still in Phase-II trials in Paroxysmal atrial fibrillation in Australia (PO) (ACTRN12618001692224)
- 25 Feb 2021 No development reported - Phase-II for Myocardial infarction in Australia, New Zealand, USA (PO)